StreetInsider.com News Articles

Ocular Therapeutix (OCUL) Reiterated at Market Outperform by Citizens Ahead of Q2 Earnings

Fri, 17 Jul 2026 05:17:50 -0400

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $34.00 price target on Ocular Therapeutix (NASDAQ: OCUL).

The analyst commented, "We reiterate our Market Outperform rating and $34 risk-adjusted, DCF-derived price target on Ocular Therapeutix. We model 2Q26 Dextenza revenue of $12M vs. consensus of $13M. While Dextenza revenues remain modest, having the sales infrastructure in place should allow for an accelerated ramp if Axpaxli gains approval in wet AMD next year (90% POS)."

For an analyst ratings summary and ratings history on Ocular Therapeutix click here. For more ratings news on Ocular Therapeutix click here.

Shares of Ocular Therapeutix

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 09 Jul 2026 16:05:00 -0400

BEDFORD, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to eleven newly hired non-executive employees. The awards were made as an inducement material to each recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement equity awards were granted effective as of July 6, 2026, and consist of non-statutory stock option awards to purchase up to an aggregate of

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 09 Jul 2026 16:05:00 -0400

The inducement equity awards were granted effective as of July 6, 2026, and consist of non-statutory stock option awards to purchase up to an aggregate of

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 09 Jul 2026 16:05:00 -0400

The inducement equity awards were granted effective as of July 6, 2026, and consist of non-statutory stock option awards to purchase up to an aggregate of

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 09 Jul 2026 16:05:00 -0400

The inducement equity awards were granted effective as of July 6, 2026, and consist of non-statutory stock option awards to purchase up to an aggregate of

Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences

Wed, 01 Jul 2026 07:00:00 -0400

BEDFORD, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in July 2026.

Upcoming Scientific Conferences:

9th Annual OIS Retina Innovation Summit (OIS Retina 2026): July 14, 2026
Montréal, Quebec

Presentation: Ocular Therapeutix: Retina Experience Redefined
Presentation Date/Time: Tuesday, July 14, 2026, 11:37 – 11:44 AM EDT
Presenter: Peter K. Kaiser, MD, Chief Development Officer

Panel Title: The Impact of Recent FDA Guidance on Drug Development
Panel Date/Time: Tuesday, July 14, 2026,

Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences

Wed, 01 Jul 2026 07:00:00 -0400

Upcoming Scientific Conferences:

9th Annual OIS Retina Innovation Summit (OIS Retina 2026): July 14, 2026
Montréal, Quebec

Presentation: Ocular Therapeutix: Retina Experience Redefined
Presentation Date/Time: Tuesday, July 14, 2026, 11:37 – 11:44 AM EDT
Presenter: Peter K. Kaiser, MD, Chief Development Officer

Panel Title: The Impact of Recent FDA Guidance on Drug Development
Panel Date/Time: Tuesday, July 14, 2026,

Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences

Wed, 01 Jul 2026 07:00:00 -0400

Upcoming Scientific Conferences:

9th Annual OIS Retina Innovation Summit (OIS Retina 2026): July 14, 2026
Montréal, Quebec

Presentation: Ocular Therapeutix: Retina Experience Redefined
Presentation Date/Time: Tuesday, July 14, 2026, 11:37 – 11:44 AM EDT
Presenter: Peter K. Kaiser, MD, Chief Development Officer

Panel Title: The Impact of Recent FDA Guidance on Drug Development
Panel Date/Time: Tuesday, July 14, 2026,

Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences

Wed, 01 Jul 2026 07:00:00 -0400

Upcoming Scientific Conferences:

9th Annual OIS Retina Innovation Summit (OIS Retina 2026): July 14, 2026
Montréal, Quebec

Presentation: Ocular Therapeutix: Retina Experience Redefined
Presentation Date/Time: Tuesday, July 14, 2026, 11:37 – 11:44 AM EDT
Presenter: Peter K. Kaiser, MD, Chief Development Officer

Panel Title: The Impact of Recent FDA Guidance on Drug Development
Panel Date/Time: Tuesday, July 14, 2026,

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 22 Jun 2026 16:05:00 -0400

BEDFORD, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to Ms. Kelley Allison, the Company’s new SVP, Market Access and Health Policy. The awards were made as an inducement material to the recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement equity awards granted to Ms. Allison were effective as of June 15, 2026 and consist of

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 22 Jun 2026 16:05:00 -0400

The inducement equity awards granted to Ms. Allison were effective as of June 15, 2026 and consist of

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 22 Jun 2026 16:05:00 -0400

The inducement equity awards granted to Ms. Allison were effective as of June 15, 2026 and consist of

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 22 Jun 2026 16:05:00 -0400

The inducement equity awards granted to Ms. Allison were effective as of June 15, 2026 and consist of

Ocular Therapeutix (OCUL) PT Raised to $25 at H.C. Wainwright

Mon, 22 Jun 2026 06:59:28 -0400

(Updated - June 22, 2026 6:59 AM EDT)

H.C. Wainwright analyst Yi Chen raised the price target on Ocular Therapeutix (NASDAQ: OCUL) to $25.00 (from $21.00) while maintaining a Buy rating.

The analyst commented: "Yesterday, Ocular Therapeutix hosted its Investor Day in NYC, in which the company discussed the outcome of its Type C meeting with the FDA and the KOLs endorsed the adoption of AXPAXLI. Notably, the company reached alignment with FDA during the May 2026 Type C meeting (with written minutes) to submit AXPAXLI NDA in wet AMD based on SOL-1 Week 52 data plus confirmatory evidence under the 505(b)(2)

Ocular Therapeutix (OCUL) PT Raised to $25 at H.C. Wainwright

Mon, 22 Jun 2026 06:59:28 -0400

(Updated - June 22, 2026 6:59 AM EDT)

H.C. Wainwright analyst Yi Chen raised the price target on Ocular Therapeutix (NASDAQ: OCUL) to $25.00 (from $21.00) while maintaining a Buy rating.

Form 4 OCULAR THERAPEUTIX, INC For: Jun 16 Filed by: Dugel Pravin

Thu, 18 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260618/26665790.html

Form 4 OCULAR THERAPEUTIX, INC For: Jun 16 Filed by: Dugel Pravin

Thu, 18 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260618/26665790.html

Ocular Therapeutix (OCUL) PT Raised to $30 at Baird

Thu, 18 Jun 2026 06:14:06 -0400

Baird analyst Colleen Kusy raised the price target on Ocular Therapeutix (NASDAQ: OCUL) to $30.00 (from $24.00) while maintaining a Outperform rating.

Ocular Therapeutix plans wet AMD drug filing for late 2026

Wed, 17 Jun 2026 08:45:32 -0400

Ocular Therapeutix, Inc. (NASDAQ: OCUL) announced it has reached alignment with the U.S. Food and Drug Administration on plans to submit a New Drug Application for AXPAXLI in wet age-related macular degeneration during the fourth quarter of 2026, according to a press release issued June 17, 2026.

The NDA will be based on data from the SOL-1 Phase 3 trial at Week 52, combined with interim safety data from the ongoing SOL-R trial. The company said it plans to conduct an interim SOL-R safety analysis in the fourth quarter of 2026 to accumulate more than 300 patients of safety data across

Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026

Wed, 17 Jun 2026 08:45:00 -0400

Per May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safety plus interim SOL-R safety data

Ocular to conduct interim SOL-R safety analysis in 4Q 2026 to reach >300 patients of safety data across SOL-1 and SOL-R, in alignment with FDA requirements

Complete AXPAXLI NDA package in wet AMD planned to be submitted in 4Q 2026

SOL-R efficacy data no longer part of the AXPAXLI NDA submission plan

Ocular will evaluate superiority of AXPAXLI vs aflibercept (8mg) Q6M at

Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026

Wed, 17 Jun 2026 08:45:00 -0400

Per May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safety plus interim SOL-R safety data

Ocular to conduct interim SOL-R safety analysis in 4Q 2026 to reach >300 patients of safety data across SOL-1 and SOL-R, in alignment with FDA requirements

Complete AXPAXLI NDA package in wet AMD planned to be submitted in 4Q 2026

SOL-R efficacy data no longer part of the AXPAXLI NDA submission plan

Ocular will evaluate superiority of AXPAXLI vs aflibercept (8mg) Q6M at

Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026

Wed, 17 Jun 2026 08:45:00 -0400

Per May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safety plus interim SOL-R safety data

Ocular to conduct interim SOL-R safety analysis in 4Q 2026 to reach >300 patients of safety data across SOL-1 and SOL-R, in alignment with FDA requirements

Complete AXPAXLI NDA package in wet AMD planned to be submitted in 4Q 2026

SOL-R efficacy data no longer part of the AXPAXLI NDA submission plan

Ocular will evaluate superiority of AXPAXLI vs aflibercept (8mg) Q6M at

Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026

Wed, 17 Jun 2026 08:45:00 -0400

Per May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safety plus interim SOL-R safety data

Ocular to conduct interim SOL-R safety analysis in 4Q 2026 to reach >300 patients of safety data across SOL-1 and SOL-R, in alignment with FDA requirements

Complete AXPAXLI NDA package in wet AMD planned to be submitted in 4Q 2026

SOL-R efficacy data no longer part of the AXPAXLI NDA submission plan

Ocular will evaluate superiority of AXPAXLI vs aflibercept (8mg) Q6M at

Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026

Wed, 17 Jun 2026 08:45:00 -0400

Per May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safety plus interim SOL-R safety data

Ocular to conduct interim SOL-R safety analysis in 4Q 2026 to reach >300 patients of safety data across SOL-1 and SOL-R, in alignment with FDA requirements

Complete AXPAXLI NDA package in wet AMD planned to be submitted in 4Q 2026

SOL-R efficacy data no longer part of the AXPAXLI NDA submission plan

Ocular will evaluate superiority of AXPAXLI vs aflibercept (8mg) Q6M at

Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026

Wed, 17 Jun 2026 08:45:00 -0400

Per May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safety plus interim SOL-R safety data

Ocular to conduct interim SOL-R safety analysis in 4Q 2026 to reach >300 patients of safety data across SOL-1 and SOL-R, in alignment with FDA requirements

Complete AXPAXLI NDA package in wet AMD planned to be submitted in 4Q 2026

SOL-R efficacy data no longer part of the AXPAXLI NDA submission plan

Ocular will evaluate superiority of AXPAXLI vs aflibercept (8mg) Q6M at